PF-Atlas › Clinical Trials › NCT00074698
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
FG-3019 · Phase 1
Registry ID
NCT00074698
Phase
Phase 1
Status
Completed
Drug / intervention
FG-3019
Sponsor
Kyntra Bio
Start
2003-12-08
Enrollment
21
Locations
4
About this trial
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor (CTGF). CTGF triggers the production of collagen and fibronectin, which cause scarring and thickening of the lungs. Participants will be assigned sequentially to one of the 3 dose group: Low, medium, and high FG-3019.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00074698 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.